PCMC
CATX icon

Planning Capital Management Corporation’s Perspective Therapeutics CATX Stock Holding History

Planning Capital Management Corporation’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.54K Buy
115
+5
+5% +$66 ﹤0.01% 610
2024
Q2 		$1.1K Buy
+110
New +$1.59K ﹤0.01% 582

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Planning Capital Management Corporation's CATX Position: Q3 2024 in Review

Planning Capital Management Corporation increased its Perspective Therapeutics (CATX) stake by 4.5% in Q3 2024, buying an estimated $66 and bringing the position to 115 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

Planning Capital Management Corporation first reported a position in CATX in Q2 2024 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold CATX as of Q3 2024.

  • Planning Capital Management Corporation held 115 shares of Perspective Therapeutics worth $1.54K as of Q3 2024.
  • Planning Capital Management Corporation bought 5 Perspective Therapeutics shares in Q3 2024, an estimated $66.
  • Perspective Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #610 holding.
  • Planning Capital Management Corporation first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 127 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.